The earnings call presented a strong performance with significant revenue growth and pipeline advancements, particularly in oncology and biopharmaceuticals. However, challenges such as Soliris biosimilar competition and Farxiga's anticipated VBP impact in China present concerns. Despite these issues, the overall outlook remains positive due to robust pipeline success and strategic growth initiatives.

Company Guidance

During AstraZeneca's H1 and Q2 2025 call, the company reported an 11% increase in total revenue for the first half of the year, driven by strong demand for innovative medicines, with core EPS growing by 17%. They achieved 19 regulatory approvals in key regions and announced results from 12 positive Phase III trials, including five new molecular entities. Oncology revenues grew by 16% to $12 billion, while biopharmaceuticals saw a 10% growth, reaching $11.2 billion. Rare disease revenues also grew by 7% in Q2. The company reiterated its guidance for a high single-digit percentage increase in revenue and a low double-digit increase in EPS for 2025. AstraZeneca is progressing with its pipeline, particularly in oncology, with significant developments in breast cancer and gastrointestinal cancers, and remains on track to meet its 2030 revenue target of $80 billion, supported by recent successful Phase III readouts in cardiovascular and rare diseases.

Strong Revenue Growth

Total revenue grew by 11% in the first half of 2025, driven by demand for innovative medicines. Core EPS grew 17%, showcasing strong financial performance.

Regulatory Approvals and Pipeline Success

Achieved 19 regulatory approvals in key regions and announced results of 12 positive Phase III trials, including for 5 new molecular entities.

Oncology Segment Performance

Oncology revenues grew 16% to $12 billion in the first half. Imfinzi and Enhertu showed strong growth with new indications and approvals.

Biopharmaceuticals Growth

Biopharmaceuticals revenue rose 10% to $11.2 billion, with R&I revenue up 13% and CVRM achieving 8% growth.

Positive Trial Results for Baxdrostat

BaxHTN Phase III trial for baxdrostat in uncontrolled hypertension met all primary and secondary endpoints, indicating a strong potential for market success.

AstraZeneca (AZNCF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AZNCF Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	2.28 / -	2.08	―	―	―
Jul 29, 2025	2025 (Q2)	2.15 / 2.17	1.98	9.60% (+0.19)	―	―
Apr 29, 2025	2025 (Q1)	2.23 / 2.49	2.06	20.87% (+0.43)	―	―
Feb 06, 2025	2024 (Q4)	2.07 / 2.09	1.45	44.14% (+0.64)	―	―
Nov 12, 2024	2024 (Q3)	2.04 / 2.08	1.73	20.23% (+0.35)	―	―
Jul 25, 2024	2024 (Q2)	1.97 / 1.98	2.15	-7.91% (-0.17)	―	―
Apr 25, 2024	2024 (Q1)	1.91 / 2.06	1.92	7.29% (+0.14)	―	―
Feb 08, 2024	2023 (Q4)	1.46 / 1.45	1.38	5.07% (+0.07)	―	―
Nov 09, 2023	2023 (Q3)	1.69 / 1.73	1.67	3.59% (+0.06)	―	―
Jul 28, 2023	2023 (Q2)	1.98 / 2.15	1.72	25.00% (+0.43)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AZNCF Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 29, 2025	$143.11	$149.44	+4.43%
Apr 29, 2025	$137.81	$143.94	+4.45%
Feb 06, 2025	$131.78	$148.25	+12.50%
Nov 12, 2024	$124.08	$125.66	+1.27%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does AstraZeneca PLC (AZNCF) report earnings?

AstraZeneca PLC (AZNCF) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).

What is AstraZeneca PLC (AZNCF) earnings time?

AstraZeneca PLC (AZNCF) earnings time is at Nov 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is AZNCF EPS forecast?

AZNCF EPS forecast for the fiscal quarter 2025 (Q3) is 2.28.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing